Esmethadone hydrochloride is a Small Molecule owned by Relmada Therapeutics, and is involved in 11 clinical trials, of which 8 were completed, and 3 are ongoing.
REL-1017 (D-methadone) is N-methyl-D-aspartate receptor antagonist. NMDA receptor antagonists reduce hyperalgesia and allodynia of neuropathic pain induced by nerve injury. Pain is mediated in part by the excitatory amino acids glutamate and aspartate binding to the N-methyl-D-aspartate (NMDA) receptor. The activation of NMDA receptors has been associated with hyperalgesia, neuropathic pain and reduced functionality of opioid receptors. D-Methadone antagonizes the action of stimulated NMDA receptors and thereby checks the CNS activity.
The revenue for Esmethadone hydrochloride is expected to reach a total of $1.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Esmethadone hydrochloride NPV Report.
Esmethadone hydrochloride is currently owned by Relmada Therapeutics.
Esmethadone hydrochloride Overview
REL-1017 (D-methadone) is under development for the treatment of major depressive disorder, treatment resistant depression. The drug candidate is administered through oral route as a solution and tablet. The drug candidate is a nonopioid analgesic which acts by targeting N-methyl-D-aspartate (NMDA) receptor. It is a d optical isomer of racemic methadone. It is a new chemical entity.
It was also under development for the treatment of post herpetic neuralgia, Rett syndrome, ophthalmology, mitochondrial diseases, amyotrophic lateral sclerosis, substance (drug) abuse and neuropathic pain and restless leg syndrome.
Relmada Therapeutics Overview
Relmada Therapeutics, formerly Camp Nine, is a clinical-stage biotechnology company. It focuses on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. The company’s pipeline product esmethadone is used for the treatment of central nervous system (CNS) diseases and other disorders. It conducts various phases of clinical trials like Phase I and II. The company also carries out research and development. Relmada Therapeutics is headquartered in Coral Gables, Florida, the US.
The operating loss of the company was US$125.7 million in FY2021, compared to an operating loss of US$60.8 million in FY2020. The net loss of the company was US$125.8 million in FY2021, compared to a net loss of US$59.5 million in FY2020.
Quick View – Esmethadone hydrochloride
|Highest Development Stage|